Literature DB >> 24643836

Phosphorylated STAT3 and PD-1 regulate IL-17 production and IL-23 receptor expression in Mycobacterium tuberculosis infection.

Anuradha Bandaru1, Kamakshi P Devalraju, Padmaja Paidipally, Rohan Dhiman, Sambasivan Venkatasubramanian, Peter F Barnes, Ramakrishna Vankayalapati, Vijayalakshmi Valluri.   

Abstract

We studied the factors that regulate IL-23 receptor expression and IL-17 production in human tuberculosis infection. Mycobacterium tuberculosis (M. tb)-stimulated CD4(+) T cells from tuberculosis patients secreted less IL-17 than did CD4(+) T cells from healthy tuberculin reactors (PPD(+) ). M. tb-cultured monocytes from tuberculosis patients and PPD(+) donors expressed equal amounts of IL-23p19 mRNA and protein, suggesting that reduced IL-23 production is not responsible for decreased IL-17 production by tuberculosis patients. Freshly isolated and M. tb-stimulated CD4(+) T cells from tuberculosis patients had reduced IL-23 receptor and phosphorylated STAT3 (pSTAT3) expression, compared with cells from PPD(+) donors. STAT3 siRNA reduced IL-23 receptor expression and IL-17 production by CD4(+) T cells from PPD(+) donors. Tuberculosis patients had increased numbers of PD-1(+) T cells compared with healthy PPD(+) individuals. Anti-PD-1 antibody enhanced pSTAT3 and IL-23R expression and IL-17 production by M. tb-cultured CD4(+) T cells of tuberculosis patients. Anti-tuberculosis therapy decreased PD-1 expression, increased IL-17 and IFN-γ production and pSTAT3 and IL-23R expression. These findings demonstrate that increased PD-1 expression and decreased pSTAT3 expression reduce IL-23 receptor expression and IL-17 production by CD4(+) T cells of tuberculosis patients.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Cytokine; Human; IL-17; M. tuberculosis

Mesh:

Substances:

Year:  2014        PMID: 24643836      PMCID: PMC4106993          DOI: 10.1002/eji.201343680

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  58 in total

1.  Functional profile of CD4+ and CD8+ T cells in latently infected individuals and patients with active TB.

Authors:  Nancy D Marín; Sara C París; Mauricio Rojas; Luis F García
Journal:  Tuberculosis (Edinb)       Date:  2013-01-16       Impact factor: 3.131

2.  IL-23R polymorphisms, HBV infection, and risk of hepatocellular carcinoma in a high-risk Chinese population.

Authors:  Yan Xu; Yao Liu; Shandong Pan; Li Liu; Jibin Liu; Xiangjun Zhai; Hongbing Shen; Zhibin Hu
Journal:  J Gastroenterol       Date:  2012-06-28       Impact factor: 7.527

3.  Increased Th17 cells and interleukin-17 contribute to immune activation and disease aggravation in patients with chronic hepatitis B virus infection.

Authors:  Bo Yang; Yadong Wang; Caiyan Zhao; Wenzhao Yan; Honghao Che; Chuan Shen; Meng Zhao
Journal:  Immunol Lett       Date:  2012-12-10       Impact factor: 3.685

4.  SOCS3 promotes interleukin-17 expression of human T cells.

Authors:  Katja Kleinsteuber; Kerrin Heesch; Stefanie Schattling; Claudia Sander-Juelch; Ulrike Mock; Kristoffer Riecken; Boris Fehse; Bernhard Fleischer; Marc Jacobsen
Journal:  Blood       Date:  2012-10-01       Impact factor: 22.113

5.  Chlamydophila pneumoniae re-infection triggers the production of IL-17A and IL-17E, important regulators of airway inflammation.

Authors:  Tímea Mosolygó; József Korcsik; Emese Petra Balogh; Ildikó Faludi; Dezső P Virók; Valéria Endrész; Katalin Burián
Journal:  Inflamm Res       Date:  2013-02-06       Impact factor: 4.575

6.  Reduced frequency of memory T cells and increased Th17 responses in patients with active tuberculosis.

Authors:  Nancy D Marín; Sara C París; Mauricio Rojas; Luis F García
Journal:  Clin Vaccine Immunol       Date:  2012-08-22

7.  T-helper 17 cells are associated with pathology in human schistosomiasis.

Authors:  Moustapha Mbow; Bridget M Larkin; Lynn Meurs; Linda J Wammes; Sanne E de Jong; Lucja A Labuda; Makhtar Camara; Hermelijn H Smits; Katja Polman; Tandakha N Dieye; Souleymane Mboup; Miguel J Stadecker; Maria Yazdanbakhsh
Journal:  J Infect Dis       Date:  2012-10-19       Impact factor: 5.226

8.  IL-17 level in patients with Dengue virus infection & its association with severity of illness.

Authors:  Amita Jain; Nidhi Pandey; R K Garg; Rashmi Kumar
Journal:  J Clin Immunol       Date:  2012-12-29       Impact factor: 8.542

9.  Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis.

Authors:  R Gopal; J Rangel-Moreno; S Slight; Y Lin; H F Nawar; B A Fallert Junecko; T A Reinhart; J Kolls; T D Randall; T D Connell; S A Khader
Journal:  Mucosal Immunol       Date:  2013-01-09       Impact factor: 7.313

10.  Overexpression of SOCS3 in T lymphocytes leads to impaired interleukin-17 production and severe aortic aneurysm formation in mice--brief report.

Authors:  Mélissa Romain; Soraya Taleb; Marion Dalloz; Padmapriya Ponnuswamy; Bruno Esposito; Nicolas Pérez; Yu Wang; Akihiko Yoshimura; Alain Tedgui; Ziad Mallat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-01-17       Impact factor: 8.311

View more
  22 in total

Review 1.  The crucial roles of Th17-related cytokines/signal pathways in M. tuberculosis infection.

Authors:  Hongbo Shen; Zheng W Chen
Journal:  Cell Mol Immunol       Date:  2017-11-27       Impact factor: 11.530

Review 2.  The role of STAT3 in tumor-mediated immune suppression.

Authors:  Sherise D Ferguson; Visish M Srinivasan; Amy B Heimberger
Journal:  J Neurooncol       Date:  2015-02-22       Impact factor: 4.130

3.  Selective Destruction of Interleukin 23-Induced Expansion of a Major Antigen-Specific γδ T-Cell Subset in Patients With Tuberculosis.

Authors:  Hongbo Shen; Jin Gu; Heping Xiao; Shanshan Liang; Enzhuo Yang; Rui Yang; Dan Huang; Crystal Chen; Feifei Wang; Ling Shen; Zheng W Chen
Journal:  J Infect Dis       Date:  2017-02-01       Impact factor: 5.226

4.  Reduced T-Helper 17 Responses to Streptococcus pneumoniae in Infection-Prone Children Can Be Rescued by Addition of Innate Cytokines.

Authors:  Saleem Basha; Ravinder Kaur; Tim R Mosmann; Michael E Pichichero
Journal:  J Infect Dis       Date:  2017-04-15       Impact factor: 5.226

Review 5.  Signal transducer and activator of transcription 3: a year in review.

Authors:  Lisa R Forbes; Josh Milner; Elie Haddad
Journal:  Curr Opin Hematol       Date:  2016-01       Impact factor: 3.284

6.  Constitutive STAT3 phosphorylation and IL-6/IL-10 co-expression are associated with impaired T-cell function in tuberculosis patients.

Authors:  Kirstin Harling; Ernest Adankwah; Alptekin Güler; Anthony Afum-Adjei Awuah; Louis Adu-Amoah; Ertan Mayatepek; Ellis Owusu-Dabo; Norman Nausch; Marc Jacobsen
Journal:  Cell Mol Immunol       Date:  2018-03-19       Impact factor: 11.530

7.  Anti-PD-L1 Therapy Does Not Improve Survival in a Murine Model of Lethal Staphylococcus aureus Pneumonia.

Authors:  Colleen S Curran; Lindsay M Busch; Yan Li; Cui Xizhong; Junfeng Sun; Peter Q Eichacker; Parizad Torabi-Parizi
Journal:  J Infect Dis       Date:  2021-12-15       Impact factor: 5.226

8.  PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment.

Authors:  Syeda S Hassan; Muhammad Akram; Elizabeth C King; Hazel M Dockrell; Jacqueline M Cliff
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

9.  Genetics and Functional Mechanisms of STAT3 Polymorphisms in Human Tuberculosis.

Authors:  Feifei Wang; Guixian Huang; Ling Shen; Ying Peng; Wei Sha; Zheng W Chen; Hongbo Shen
Journal:  Front Cell Infect Microbiol       Date:  2021-07-07       Impact factor: 5.293

10.  Plasma Biomarkers Can Predict Treatment Response in Tuberculosis Patients: A Prospective Observational Study.

Authors:  Meng-Rui Lee; Chia-Jung Tsai; Wei-Jie Wang; Tzu-Yi Chuang; Chih-Mann Yang; Lih-Yu Chang; Ching-Kai Lin; Jann-Yuan Wang; Chin-Chong Shu; Li-Na Lee; Chong-Jen Yu
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.